Cargando…
Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease
Hypercalcemia most often results from primary hyperparathyroidism and malignancy. Adynamic bone disease (ABD) is a form of renal osteodystrophy characterized by reduced bone turnover, which can limit the ability of bone to release or store calcium, potentially leading to low, normal, or high serum c...
Autores principales: | Peugh, Jennifer, Khalil, Andrew, Chan, Micah R, Hansen, Karen E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659444/ https://www.ncbi.nlm.nih.gov/pubmed/31372586 http://dx.doi.org/10.1002/jbm4.10176 |
Ejemplares similares
-
Treatment of adynamic bone disease in a haemodialysis patient with teriparatide
por: Giamalis, Panagiotis, et al.
Publicado: (2015) -
Bone histomorphometry after treatment with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy
por: Lehmann, Gabriele, et al.
Publicado: (2009) -
Severe hypercalcemia due to teriparatide
por: Karatoprak, Cumali, et al.
Publicado: (2012) -
Adynamic bone disease
por: Gueiros, Ana Paula Santana, et al.
Publicado: (2021) -
Teriparatide Induced Delayed Persistent Hypercalcemia
por: Thiruchelvam, Nirosshan, et al.
Publicado: (2014)